123 related articles for article (PubMed ID: 7338557)
21. A controlled study on the antihypertensive effect of a new beta-adrenergic receptor blocking drug, metoprolol, in combination with chlorthalidone.
Jäättelä A; Pyörälä K
Br J Clin Pharmacol; 1976 Aug; 3(4):655-60. PubMed ID: 22216509
[TBL] [Abstract][Full Text] [Related]
22. Comparison of single-dose pharmacokinetic and pharmacodynamic properties of two metoprolol Oros systems with different initial zero-order release rates.
Warrington SJ; Barclay SP; John VA; Shotton PA; Good W
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):225S-230S. PubMed ID: 4005127
[TBL] [Abstract][Full Text] [Related]
23. [Double-blind comparative study of the hypotensive effect of combination therapy with chlorthalidone and metoprolol or alpha-methyldopa].
Guidi G; Giuntoli F; Galeone F; Checchi M; Locci P; Saba GC; Saba P
G Clin Med; 1981 Aug; 62(8):558-66. PubMed ID: 7030853
[No Abstract] [Full Text] [Related]
24. Angiotensin-converting enzyme inhibition and the combination of a beta blocker and a diuretic are equally effective in lowering proteinuria in patients with glomerulonephritis.
Kloke HJ; Wetzels JF; van Hamersvelt HW; Koene RA; Huysmans FT
Nephrol Dial Transplant; 1993; 8(9):808-13. PubMed ID: 8255512
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.
Jordö L; Attman PO; Aurell M; Johansson L; Johnsson G; Regårdh CG
Clin Pharmacokinet; 1980; 5(2):169-80. PubMed ID: 6102500
[TBL] [Abstract][Full Text] [Related]
26. Hemodynamic effects of once a day administration of combined chlorthalidone and metoprolol slow-release in essential hypertension.
Pomidossi G; Parati G; Motolese M; Mancia G; Zanchetti A
Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):665-71. PubMed ID: 6526542
[TBL] [Abstract][Full Text] [Related]
27. A controlled study on the anti-hypertensive effect of a new beta-adrenoreceptor-blocking drug, metoprolol, in combination with chlorthalidone.
Jäättelä A; Pyörälä K
Clin Sci Mol Med Suppl; 1976 Dec; 3():521s-523s. PubMed ID: 799561
[TBL] [Abstract][Full Text] [Related]
28. Age and responses to isometric exercise in hypertension: possible predictors of the antihypertensive effect of diuretics and beta-blockers.
Corea L; Valori C; Bentivoglio M; Verdecchia P; Bichisao E
Int J Clin Pharmacol Ther Toxicol; 1985 Oct; 23(10):554-9. PubMed ID: 2866164
[TBL] [Abstract][Full Text] [Related]
29. [Use of metoprolol and atenolol, singly or in combination with a diuretic, in the treatment of arterial hypertension].
Centritto V
Boll Soc Ital Cardiol; 1980; 25(5):451-7. PubMed ID: 7284149
[No Abstract] [Full Text] [Related]
30. Pharmacokinetics of atenolol in hypertensive subjects with and without co-administration of chlorthalidone.
Riva E; Farina PL; Sega R; Tognoni G; Bastain W; McAinsh J
Eur J Clin Pharmacol; 1980 May; 17(5):333-7. PubMed ID: 7418712
[TBL] [Abstract][Full Text] [Related]
31. Plasma levels and negative chronotropic effect of metoprolol following single doses of a conventional and sustained-release formulation.
Quaterman CP; Kendall MJ; Welling PG
Eur J Clin Pharmacol; 1979 Mar; 15(2):97-103. PubMed ID: 436924
[TBL] [Abstract][Full Text] [Related]
32. Total body potassium in patients receiving chlorthalidone and metoprolol for hypertension.
Gray JM; Lawson DH; Boddy K; East W
Scott Med J; 1983 Apr; 28(2):172-5. PubMed ID: 6867699
[TBL] [Abstract][Full Text] [Related]
33. Bioavailability in man of atenolol and chlorthalidone from a combination formulation.
McAinsh J; Bastain W; Young J; Harry JD
Biopharm Drug Dispos; 1981; 2(2):147-56. PubMed ID: 7248478
[TBL] [Abstract][Full Text] [Related]
34. Effect of rifampicin on metoprolol and antipyrine kinetics.
Bennett PN; John VA; Whitmarsh VB
Br J Clin Pharmacol; 1982 Mar; 13(3):387-91. PubMed ID: 7059439
[TBL] [Abstract][Full Text] [Related]
35. A multiple dose pharmacokinetic and pharmacodynamic evaluation of conventional and 19/285 Oros formulations of metoprolol in healthy volunteers.
Grainger SL; John VA; Shotton PA; Smith SE
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):239S-244S. PubMed ID: 4005129
[TBL] [Abstract][Full Text] [Related]
36. Oros controlled-release formulations of metoprolol: an approach to the development of a system for once daily administration.
Good W; Leeson LJ; Zak SL; Wagner WE; Meeker JB; Arnold JD
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):231S-238S. PubMed ID: 4005128
[TBL] [Abstract][Full Text] [Related]
37. Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications.
Kendall MJ; Maxwell SR; Sandberg A; Westergren G
Clin Pharmacokinet; 1991 Nov; 21(5):319-30. PubMed ID: 1773547
[TBL] [Abstract][Full Text] [Related]
38. Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.
Benfield P; Clissold SP; Brogden RN
Drugs; 1986 May; 31(5):376-429. PubMed ID: 2940080
[TBL] [Abstract][Full Text] [Related]
39. The comparative beta-adrenoceptor blocking effects of penbutolol, atenolol and sustained-release metoprolol in healthy volunteers.
Mucklow JC; Kuhn S
Eur J Clin Pharmacol; 1984; 27(3):269-73. PubMed ID: 6510453
[TBL] [Abstract][Full Text] [Related]
40. The pharmacodynamic and pharmacokinetic profiles of controlled-release formulations of felodipine and metoprolol in free and fixed combinations in elderly hypertensive patients.
McLay JS; MacDonald TM; Hosie J; Elliott HL;
Eur J Clin Pharmacol; 2000 Nov; 56(8):529-35. PubMed ID: 11151741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
